BASINGSTOKE, England and PHILADELPHIA, May 09, 2008 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announces that ordinary shareholders approved the scheme of arrangement proposed in a circular to shareholders dated 16 April 2008 (the "Circular"), without modification, at a meeting convened by the Court and held today.

RIDGEFIELD, Conn., May 09, 2008 /PRNewswire/ -- Xmark Opportunity Partners, LLC, the investment manager to Xmark Opportunity Fund, L.P., Xmark Opportunity Fund, Ltd. and Xmark JV Investment Partners, LLC, announced today that it fully supports the initiatives outlined in the press release issued by Genaera Corporation on May 8, 2008 with respect to executive base compensation, cash incentives to executives, workforce reduction and the streamlining of expenditures.

RADNOR, Pa.--(BUSINESS WIRE)--May 9, 2008 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.

HORSOLM, Denmark, May 9, 2008-Summary: The board of directors of Pharmexa has today issued warrants to Chief Executive Officer Jakob Schmidt as authorised by the annual general meeting. The issued warrants allow for subscription of 600,000 shares of nominally DKK 5 each in Pharmexa by cash payment, equal to a nominal value of DKK 3,000,000. The exercise price will be DKK 3.54 per share of nominally DKK 5 with an additional 10% p.a. per running year from the allocation date and until the exercise date. However, the exercise price will never be less than DKK 5 per share of nominally DKK 5.

COLUMBUS, Ohio (May 9, 2008) -- To support customers in their aim to be compliant with applicable industry standards, METTLER TOLEDO has created the Initial Qualification Packages (IPacs) and the Equipment Qualification Pac (EQ Pac). These qualification services offer customers significant cost savings through quick installation, optimal equipment set-up and configuration resulting in longevity and safe operation by trained users, and ensuring compliance with quality management systems such as GLP/GMP or other quality management system assessments.

CALGARY, May 09, 2008 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announced today that it has begun patient enrolment in a clinical trial using intravenous administration of Reolysin in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers.

KENILWORTH, N.J., May 09, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation will hold its Annual Meeting of Shareholders Friday, May 16, 2008, in Memphis, Tenn. At 8 a.m. (CDT) (9 a.m. EDT) on that day, a live Webcast of the meeting will be available to all interested parties via the corporate Web site, www.schering-plough.com.

LONDON, 09 May 2008 -Throughout May, Pharmaceutical Profiles (Ruddington, UK) is maintaining its focus on innovative clinical and pre-clinical protocols that support effective and efficient drug development. The company's latest webinar and workshop schedule includes events that address important issues, including: gaining an early understanding of bioavailability, optimizing formulation strategy for efficient development, and testing the feasibility of controlled release delivery.

MINNEAPOLIS--(BUSINESS WIRE)--May 9, 2008 - Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Monday, June 2, 2008 in New York City from 9 a.m. - 12:30 p.m. Eastern Daylight Time. The meeting will include remarks from the management team highlighting its plans for delivering sustainable top and bottom line growth.

RADNOR, PA – May 9, 2008 -- IndiPharm has announced that James A. Bannon, former Group President, Late Stage Development Services, Covance, Inc., has joined IndiPharm as Executive Chairman.

MCLEAN, Va. and BUDAPEST, Hungary, May 09, 2008 /PRNewswire/ -- Genetic Immunity, a US/Hungarian clinical-stage Company focused on the development of its patented nanomedicines for targeted immune amplification, announced today that the Company will be presenting at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 9, 2008 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31, 2008.